Spectrum Failed To Heed FDA Advice On Apaziquone, And Is Paying The Price
Executive Summary
FDA's original advice against NDA submission foreshadows advisory committee conclusion that substantial evidence of efficacy in bladder cancer not demonstrated by two negative trials and a post hoc pooled analysis.